RBC names Gilead a top biotech pick based on valuation

This post was originally published on this site

A scientist at Gilead Sciences analyzes patient antibody levels at the Gilead laboratory in Foster City, Calif.

David Paul Morris | Bloomberg | Getty Images

Now is a good entry point into Gilead’s stock as the company begins to stabilize, while still trading at a discount to its peers, according to RBC Capital Markets.

The firm named biotechnology company Gilead to its top picks list and maintained its $91 price target, a near 34% upside.

Add Comment